EMVision Medical Devices Limited provided an update on its clinical trial and achievement of an important technical development milestone. The pre-validation phase of the clinical trial is on schedule, with approximately half of the 30 participants for Stage 1 (healthy volunteers) having now been successfully enrolled. It is anticipated that all 30 participants will be enrolled in the coming weeks, at which point Stage 2 of the trial will be activated, involving up to 150 acute stroke/stroke mimic patients.

The device's ease of use by operators and comfort for participants has been observed, while no device-related adverse events have been reported. The Company is also pleased to advise that it has successfully achieved an important technical development milestone for its portable imaging devices under the Commonwealth of Australia Medical Research Future Fund (MRFF) program in partnership with the Australian Stroke Alliance (ASA). This has triggered a $600,000 milestone payment from the ASA.

The milestone activities focused on extensive benchtop (phantom brain and complex simulation) experiments designed to mimic clinical use of the EMVision technology to support stroke subtype diagnosis. Pleasingly, both the existing 1st Gen system and the 2nd Gen road and air ambulance device, currently under development, demonstrated high levels of performance in these experiments. As a result, a full 3D 2nd Gen antenna array has been fabricated for further verification and development.

EMVision is targeting road/air ambulance trials next year.